Tuesday, May 26, 2020
Home Authors Posts by Editor / Curator

Editor / Curator

246 POSTS 0 COMMENTS
Superbug News

Drug Resistance Could Kill 10M People per year by 2050, Experts...

Editor / Curator -
Superbug News

CDC’s Worst-Case Coronavirus Model: 214 Million Infected, 1.7 Million Dead (Intelligencer)

Editor / Curator -
American BriVision
Biotech News

American BriVision (ABVC) Improves Working Capital and Reduce Debt.

Editor / Curator -
All News

FDA Authorizes Athersys (ATHX) to Initiate a Pivotal Clinical Trial!

Editor / Curator -
Biotech News

Qiming Venture Partners Raises $1.1 Billion Fund VII

Editor / Curator -
Biotech Stock Review, Exsosomes
Biotech News

Exosomes, Extracellular Vesicles, and the CoronaVirus.

Editor / Curator -
Corbus Pharma, Biotech Stock Review
All News

Adding Corbis Pharma (CRBP) $5.55 to Watch List.

Editor / Curator -
Athersys, Biotech Stock Review
Superbug News

Boo Ya. Brokerage Sets $12 Price Target for Athersys (ATHX) $2.96.

Editor / Curator -
All News

Adding Organicell (BPSR) $0.02 to the Watch List.

Editor / Curator -
America BriVision, Biotech Stock Review
Incubator

Adding American BriVision (ABVC) $2.00 to Watch List.

Editor / Curator -
1234...25Page 3 of 25

Latest article

Immunomedics, Biotech Stock Review

Immunomedics (IMMU) $33 | Raising Price Potential to $60. American BriVision (ABVC) $3.00 |...

Biotech News Editor / Curator -
We Are Raising the Price Potential of Immunomedics (IMMU) to $60, Highest on the Street, and Initiating Coverage on Another $3.00 Medical...
Organicell

Corona Craziness Continues. Organicell (BPSR) Gains 10-fold or 1000%, in Six Weeks.

Superbug News Editor / Curator -
Too bad we don't trade for a living! We don't even use real-time quotes, LOL. $0.02 to $0.27, from Easter - what...

MRSA: Can Kill Within 24 Hours. Here Are Some Basics.

Superbug News Editor / Curator -
RESIST THE RESISTANCE: A PRIMER ON ANTIBIOTICS & ANTIBIOTIC RESISTANCE (2013) I was going to write this week about...
The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
Contact us: roland@institutionalanalyst.com
© Managed by Revelers.IO Media Group Inc.